TABLE 1.
Baseline characteristics of non‐metastatic clear cell patients who underwent surgical therapy in TCGA stratified by stage
| Stage I (n = 221, 60.05%) | Stage II (n = 47, 12.77%) | Stage III (n = 97, 26.36%) | p‐value | |
|---|---|---|---|---|
| Age (years), median (IQR) | 59 [50–68] | 58 [48–68] | 63 [52–71] | 0.034* |
| Sex | 0.124 | |||
| Female | 87 (39.37) | 11 (23.40) | 29 (29.90) | |
| Male | 134 (60.63) | 36 (76.60) | 68 (70.10) | |
| Primary tumor size, median (IQR) | 4.00 [3.10–5.20] | 9.00 [7.80–10.50] | 7.10 [5.50–10.57] | <0.001* |
| Tumor necrosis | 0.85 | |||
| Absent | 85 (91.40) | 12 (85.71) | 31 (88.57) | |
| Present | 8 (8.60) | 2 (14.29) | 4 (11.43) | |
| Tumor grade | <0.001* | |||
| G1 | 12 (5.45) | 1 (2.17) | 0 (0.00) | |
| G2 | 131 (59.55) | 20 (43.48) | 31 (31.96) | |
| G3 | 71 (32.27) | 20 (43.48) | 50 (51.55) | |
| G4 | 5 (2.27) | 4 (8.70) | 16 (16.49) | |
| GX | 1 (0.45) | 1 (2.17) | 0 (0.00) | |
| T stage | <0.001* | |||
| T1 | 220 (99.55) | 0 (0.00) | 2 (2.06) | |
| T2 | 0 (0.00) | 47 (100.00) | 1 (1.03) | |
| T3 | 1 (0.45) | 0 (0.00) | 94 (96.91) | |
| N stage | <0.001* | |||
| N0 | 82 (37.10) | 31 (65.96) | 49 (50.52) | |
| N1 | 0 (0.00) | 0 (0.00) | 10 (10.31) | |
| NX | 139 (62.90) | 16 (34.04) | 38 (39.18) | |
| SSIGN | <0.001* | |||
| Low | 155 (70.14) | 7 (14.89) | 0 (0.00) | |
| Intermediate | 62 (28.05) | 36 (76.60) | 37 (38.14) | |
| High | 4 (1.81) | 4 (8.51) | 60 (61.86) | |
| Recurrence score | <0.001* | |||
| Low | 164 (74.21) | 22 (46.81) | 43 (44.33) | |
| Intermediate | 35 (15.84) | 15 (31.91) | 36 (37.11) | |
| High | 22 (9.95) | 10 (21.28) | 18 (18.56) |
*
Statistical significance.